Article Text

Download PDFPDF
Randomised controlled trial
Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants
  1. Kyaw Soe,
  2. Kathleen M Dungan
  1. The Ohio State University, Columbus, Ohio, USA
  1. Correspondence to : Dr Kathleen M Dungan, The Ohio State University, 5th floor, McCampbell Hall, 1581 Dodd Dr, Columbus, OH 43210, USA; kathleen.dungan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Obesity is a major health problem of the 21st century and has been one of the primary contributors to the rising prevalence of type 2 diabetes mellitus (T2DM). A 5–10% loss of total body weight can reduce risk of T2DM onset.1 However, it is challenging to achieve and maintain weight loss that is sufficient for sustained metabolic benefits. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was initially developed for treatment of hyperglycaemia in patients with T2DM. It was also noted to have non-glycaemic benefits such as weight loss2 and …

View Full Text


  • Contributors KMD and KS contributed equally to writing and revising this manuscript.

  • Competing interests KMD serves as site primary investigator for multicenter trials sponsored by Sanofi, GSK, Grifols, Merck, Astra Zeneca and Regeneron and as primary investigator for investigator initiated trial funded by Merck. KMD is involved in advising activities for Eli Lilly and consulting activities for GSK. KS serves as site primary investigator for multicenter trials sponsored by Eli Lilly.

  • Provenance and peer review Commissioned; internally peer reviewed.